Replimune Group

REPLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.013 B

$12.06 -6.22%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$313.9M

Loss-making

Shares outstanding

83,945,161

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#49Cullinan TherapeuticsCGEM$1.09B
#50Odyssey TherapeuticsODTX$1.02B
#51Replimune GroupREPL$1.01B
#52Sana BiotechnologySANA$979.6M
#53Attovia TherapeuticsATTO$919.3M

Where these numbers come from

Share counts and financials for Replimune Group are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.